Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion

作者: Meit Björndahl , Renhai Cao , Anna Eriksson , Yihai Cao

DOI: 10.1161/01.RES.0000129194.61747.BF

关键词:

摘要: Vascular endothelial growth factor (VEGF)/vascular permeability is one of the most frequently expressed angiogenic factors in several pathological tissues. Development VEGF antagonists has become an important approach treatment angiogenesis-dependent diseases. Here we describe a novel anti-VEGF strategy by preventing secretion VEGF. We utilize fact that placenta (PlGF)-1, member family lacking detectable activity, preferentially forms intracellular heterodimers with cells coexpressing both factors. constructed retroviral vector containing human PlGF-1 or C-terminal KDEL sequence, which mammalian retention signal for endoplasmic reticulum. Transduction murine Lewis lung carcinoma retro-hPlGF-1-KDEL construct almost completely abrogated tumor growth. Consistent dramatic antitumor effect, mouse molecules remained as mVEGF/hPlGF-1 heterodimers, and only negligible amount mVEGF homodimers were secreted. As result, hPlGF-1-KDEL-expressing tumors, blood vessels at very low numbers lacked branching capillary networks. Gene transfer hVEGF-KDEL into likewise produced effect. Thus, our study provides antiangiogenic

参考文章(42)
U. Eriksson, K. Alitalo, Structure, Expression and Receptor-Binding Properties of Novel Vascular Endothelial Growth Factors Current Topics in Microbiology and Immunology. ,vol. 237, pp. 41- 57 ,(1999) , 10.1007/978-3-642-59953-8_3
Alitalo K, Maglione D, Aprelikova O, Viglietto G, Chou Jy, Ferraro Mg, Lei Kj, Del Vecchio S, Guerriero, Persico Mg, Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene. ,vol. 8, pp. 925- 931 ,(1993)
M. G. Persico, V. Vincenti, T. DiPalma, Structure, Expression and Receptor-Binding Properties of Placenta Growth Factor (PlGF) Current Topics in Microbiology and Immunology. ,vol. 237, pp. 31- 40 ,(1999) , 10.1007/978-3-642-59953-8_2
Taija Mäkinen, Lotta Jussila, Tanja Veikkola, Terhi Karpanen, Mikko I. Kettunen, Kalevi J. Pulkkanen, Risto Kauppinen, David G. Jackson, Hajime Kubo, Shin-Ichi Nishikawa, Seppo Ylä-Herttuala, Kari Alitalo, Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 Nature Medicine. ,vol. 7, pp. 199- 205 ,(2001) , 10.1038/84651
Ayako Yukita, Hideo Suzuki, Shinichi Kondo, Makoto Asano, Tomoe Matsumoto, Inhibition of Tumor Growth and Metastasis by an Immunoneutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor/Vascular Permeability Factor121 Cancer Research. ,vol. 55, pp. 5296- 5301 ,(1995)
Norihiko Tamaki, Takayoshi Kuno, Takeshi Takamoto, Masato Sasaki, Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival. The Kobe journal of the medical sciences. ,vol. 47, pp. 181- 191 ,(2001)
Mihaela Skobe, Thomas Hawighorst, David G. Jackson, Remko Prevo, Lauren Janes, Paula Velasco, Lucia Riccardi, Kari Alitalo, Kevin Claffey, Michael Detmar, Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis Nature Medicine. ,vol. 7, pp. 192- 198 ,(2001) , 10.1038/84643
Bronislaw Pytowski, William O’Connor, Daniel J. Hicklin, Andrea Hooper, Yiwen Li, Karen King, Angel Santiago, Peter Bohlen, James Huber, Jay Overholser, Larry Witte, Marie Prewett, Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors Cancer Research. ,vol. 59, pp. 5209- 5218 ,(1999)
Napoleone Ferrara, Kari Alitalo, None, Clinical applications of angiogenic growth factors and their inhibitors Nature Medicine. ,vol. 5, pp. 1359- 1364 ,(1999) , 10.1038/70928